207 related articles for article (PubMed ID: 22701364)
1. Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil.
Teste IS; Tamos YM; Cruz YR; Cernada AM; Rodríguez JC; Martínez NS; Antich RM; González-Quevedo A; Rodríguez JC
ScientificWorldJournal; 2012; 2012():607498. PubMed ID: 22701364
[TBL] [Abstract][Full Text] [Related]
2. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia.
Rodríguez Cruz Y; Mengana Támos Y; Muñoz Cernuda A; Subirós Martines N; González-Quevedo A; Sosa Testé I; García Rodríguez JC
ScientificWorldJournal; 2010 Nov; 10():2288-300. PubMed ID: 21103798
[TBL] [Abstract][Full Text] [Related]
3. Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain.
Gao Y; Mengana Y; Cruz YR; Muñoz A; Testé IS; García JD; Wu Y; Rodríguez JC; Zhang C
J Histochem Cytochem; 2011 Feb; 59(2):214-27. PubMed ID: 21339183
[TBL] [Abstract][Full Text] [Related]
4. Nonhematopoietic variants of erythropoietin in ischemic stroke: need for step-wise proof-of-concept studies.
Hermann DM
ScientificWorldJournal; 2010 Nov; 10():2285-7. PubMed ID: 21103797
[TBL] [Abstract][Full Text] [Related]
5. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
Garcia-Rodriguez JC; Sosa-Teste I
ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
[TBL] [Abstract][Full Text] [Related]
6. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
[TBL] [Abstract][Full Text] [Related]
7. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment.
Parra AL; Rodriguez JC
Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):60-8. PubMed ID: 22376076
[TBL] [Abstract][Full Text] [Related]
8. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.
Rodríguez Cruz Y; Strehaiano M; Rodríguez Obaya T; García Rodríguez JC; Maurice T
J Alzheimers Dis; 2017; 55(1):231-248. PubMed ID: 27662300
[TBL] [Abstract][Full Text] [Related]
9. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
Merelli A; Caltana L; Lazarowski A; Brusco A
Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
[TBL] [Abstract][Full Text] [Related]
10. Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats.
Merelli A; Caltana L; Girimonti P; Ramos AJ; Lazarowski A; Brusco A
Neurotox Res; 2011 Aug; 20(2):182-92. PubMed ID: 21116766
[TBL] [Abstract][Full Text] [Related]
11. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia.
Yu YP; Xu QQ; Zhang Q; Zhang WP; Zhang LH; Wei EQ
Neurosci Lett; 2005 Oct; 387(1):5-10. PubMed ID: 16054296
[TBL] [Abstract][Full Text] [Related]
12. Intranasal erythropoietin therapy in nervous system disorders.
Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M
Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin delivered via intra-arterial infusion reduces endoplasmic reticulum stress in brain microvessels of rats following cerebral ischemia and reperfusion.
Zhao H; Wang R; Wu X; Liang J; Qi Z; Liu X; Min L; Ji X; Luo Y
J Neuroimmune Pharmacol; 2015 Mar; 10(1):153-61. PubMed ID: 25626440
[TBL] [Abstract][Full Text] [Related]
14. The effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats.
Cetin A; Nas K; Büyükbayram H; Ceviz A; Olmez G
Eur Spine J; 2006 Oct; 15(10):1539-44. PubMed ID: 16547753
[TBL] [Abstract][Full Text] [Related]
15. Intranasal Erythropoietin Protects CA1 Hippocampal Cells, Modulated by Specific Time Pattern Molecular Changes After Ischemic Damage in Rats.
Macias-Velez RJ; Fukushima-Díaz de León L; Beas-Zárate C; Rivera-Cervantes MC
J Mol Neurosci; 2019 Aug; 68(4):590-602. PubMed ID: 31054091
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms.
Zhang F; Signore AP; Zhou Z; Wang S; Cao G; Chen J
J Neurosci Res; 2006 May; 83(7):1241-51. PubMed ID: 16511866
[TBL] [Abstract][Full Text] [Related]
17. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation.
Fletcher L; Kohli S; Sprague SM; Scranton RA; Lipton SA; Parra A; Jimenez DF; Digicaylioglu M
J Neurosurg; 2009 Jul; 111(1):164-70. PubMed ID: 19284235
[TBL] [Abstract][Full Text] [Related]
18. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
Merelli A; Czornyj L; Lazarowski A
Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
[TBL] [Abstract][Full Text] [Related]
20. [Erythropoietin--a new therapy in cerebral ischemia?].
Kalialis LV; Olsen NV
Ugeskr Laeger; 2003 Jun; 165(24):2477-81. PubMed ID: 12872467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
